Table 1.
Characteristics of the participants
| Ciprofol group (n = 40) | Propofol group (n = 38) | P | |
|---|---|---|---|
| Biological sex (n) | 0.622 | ||
| Male | 22(55%) | 23(61%) | |
| Female | 18(45%) | 15(39%) | |
| Age (years) | 64.71 ± 6.32 | 63.18 ± 4.71 | 0.231 |
| BMI (kg/m2) | 23.27 ± 2.65 | 23.89 ± 2.82 | 0.320 |
| ASA class III | 27(67%) | 29(76%) | 0.387 |
| ASA class IV | 13(33%) | 9(24%) | |
| NYHA class II | 35(87%) | 32(84%) | 0.677 |
| NYHA class III | 5(13%) | 6(16%) | |
| Merger disease (n) | |||
| Hypertension | 31(78%) | 27(71%) | 0.515 |
| Diabetes | 2358%) | 19(50%) | 0.507 |
| Stroke | 3(8%) | 3(8%) | 0.948 |
| Type of surgery (n) | |||
| CABG | 29(73%) | 31(82%) | 0.342 |
| Heart valve replacement | 11(27%) | 7(18%) | |